Search alternatives:
increase decrease » increased release (Expand Search), increased crash (Expand Search)
portion decrease » proportional decrease (Expand Search)
point decrease » point increase (Expand Search)
Showing 1,841 - 1,860 results of 13,439 for search '(( significant ((portion decrease) OR (point decrease)) ) OR ( significant increase decrease ))', query time: 0.59s Refine Results
  1. 1841
  2. 1842
  3. 1843
  4. 1844
  5. 1845
  6. 1846
  7. 1847
  8. 1848
  9. 1849
  10. 1850
  11. 1851
  12. 1852
  13. 1853

    CHAMPS pilot Hb dataset. by Jeanie du Toit (20721918)

    Published 2025
    “…Postmortem testing showed a significant decrease in hemoglobin concentrations compared to antemortem levels. …”
  14. 1854
  15. 1855

    Data Sheet 2_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  16. 1856

    Data Sheet 3_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  17. 1857

    Data Sheet 1_Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE.pdf by Mi-Ae Lyu (20413646)

    Published 2025
    “…The addition of ruxolitinib increases UCB-Treg cell persistence in peripheral blood in vivo and decreases the soluble form of human inflammatory cytokines including IFN-γ, TNF-α, and sCD40L in plasma along with improvement of skin lesions in SLE xenografts. …”
  18. 1858
  19. 1859
  20. 1860